Literature DB >> 32294320

Tetroxanes as New Agents against Leishmania amazonensis.

Isabel V Antolínez1, Luiz C A Barbosa1, Tatiane F Borgati1,2, Almodvar Baldaia1, Sebastião R Ferreira3, Raquel M Almeida4, Ricardo T Fujiwara4.   

Abstract

Leishmaniasis is a neglected disease, caused by a parasite of Leishmania genus and widespread in the tropical and subtropical areas of the world. Currents drugs are limited due to their toxicity and parasite resistance. Therefore, the discovery of new treatment, more effective and less toxic, is urgent. In this study, we report the synthesis of six gem-dihydroperoxides (2a-2f), with yields ranging from 10 % to 90 %, utilizing a new methodology. The dihydroperoxides were converted into ten tetroxanes (3a-3j), among which six (3b, 3c, 3d, 3g, 3h and 3j) showed activity against intracellular amastigotes of Leishmania amazonensis. The cytotoxicity of all compounds was also evaluated against canine macrophages (DH82), human hepatoma (HepG2) and monkey renal cells (BGM). Most compounds were more active and less toxic than potassium antimonyl tartrate trihydrate, used as positive control. Amongst all tetroxanes, 3b (IC50 =0.64 μm) was the most active, being more selective than positive control in relation to DH82, HepG2 and BGM cells. In summary, the results revealed a hit compound for the development of new drugs to treat leishmaniasis.
© 2020 Wiley-VHCA AG, Zurich, Switzerland.

Entities:  

Keywords:  antileishmanial peroxides; cytotoxicity; drug discovery; macrophage cell lines; tetraoxane

Mesh:

Substances:

Year:  2020        PMID: 32294320     DOI: 10.1002/cbdv.202000142

Source DB:  PubMed          Journal:  Chem Biodivers        ISSN: 1612-1872            Impact factor:   2.408


  1 in total

1.  Synthesis, Structure and Antileishmanial Evaluation of Endoperoxide-Pyrazole Hybrids.

Authors:  Patrícia S M Amado; Inês C C Costa; José A Paixão; Ricardo F Mendes; Sofia Cortes; Maria L S Cristiano
Journal:  Molecules       Date:  2022-08-24       Impact factor: 4.927

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.